International trade law, plain packaging and tobacco industry political activity: the Trans-Pacific Partnership

Gary Fooks, Anna B Gilmore

ABSTRACT
Tobacco companies are increasingly turning to trade and investment agreements to challenge measures aimed at reducing tobacco use. This study examines their efforts to influence the Trans-Pacific Partnership (TPP), a major trade and investment agreement which may eventually cover 40% of the world’s population; focusing on how these efforts might enhance the industry’s power to challenge the introduction of plain packaging. Specifically, the paper discusses the implications for public health regulation of Philip Morris International’s interest in using the TPP to: shape the bureaucratic structures and decision-making processes of business regulation at the national level; introduce a higher standard of protection for trademarks than is currently provided under the Agreement on Trade Related Aspects of Intellectual Property Rights; and expand the coverage of Investor-State Dispute Settlement which empowers corporations to litigate directly against governments where they are deemed to be in breach of investment agreements. The large number of countries involved in the TPP underlines its risk to the development of tobacco regulation globally.

BACKGROUND
The TPP
The TPP has its origins in a proposal made by the USA in 1998 to Australia, Chile, New Zealand and Singapore for a free trade agreement which would encourage other Asia Pacific Economic Cooperation (APEC) members to liberalise their trade.18 The initiative led to the Trans-Pacific Strategic Economic Partnership Agreement which contained an accession clause permitting other countries to join and create the basis for a larger agreement covering the entire APEC region.18–20 In 2007, negotiations began for the TPP, a significantly expanded version of the agreement, encompassing a larger group of countries.19 Negotiating states currently include the USA, Australia, New Zealand, Chile, Peru, Singapore, Malaysia, Vietnam, Brunei, Canada and Mexico.17 21 22 Their aim is to produce an agreement that other countries in the APEC grouping will adopt, creating a Free Trade Area of the Asia Pacific which the United States Trade Representative (USTR) hopes will eventually cover 40% of the world’s population.23 In November 2012, Thailand became the latest state to formally express an interest in joining.24

Described by its critics as a bill of rights for large corporations, which fundamentally shifts the balance of power between business and government, the TPP follows other investment treaties in extending protection to a wide range of proprietary interests, including contract rights, intellectual property (IP) and market share.19 25–30 Negotiations have been conducted almost entirely in secret. A decision to keep negotiating texts confidential until 4 years after a deal is completed has opened up the process to criticism that it is effectively allowing negotiators to rewrite domestic regulation without democratic scrutiny.31 The fact that representatives of corporations in the USA serve as official advisers, have full access to draft texts of the agreement, and a special role in negotiations has reinforced concerns that the final draft of the agreement will radically extend corporate property rights.31

PMMI’s interest in and efforts to shape the TPP
While there is some evidence to suggest that other big tobacco companies have been using the anonymity provided by industry associations to influence the TPP,32 PMI’s objectives for the agreement are publicly accessible. In its 2010 response to a US Federal Register notice,33 the company called for three main proposals: ’harmonization of legitimate, science-based regulations’, an investor-state dispute mechanism, and a comprehensive ‘Trade Related Aspects of Intellectual Property Rights (TRIPS)-plus’ IP chapter comprising ‘a high standard of protection for
Box 1 International Trade and Investment Law, Tobacco Industry Litigation, and Pack Branding

Trade and Investment Law
The key institution in the governance of international trade and investment is the World Trade Organisation (WTO). The organisation oversees a large number of multinational agreements which member countries must ratify on accession, and, unusually for a trade and investment regime, has its own standing body to settle disputes (see box 2 and below in the main text). The Organisation operates alongside a large number of bilateral and regional agreements. Bilateral investment treaties (BITs) are more significant in quantitative terms (estimated at 2833 at the beginning of 2012). However, the annual number of new bilateral agreements is in decline, while efforts to develop and extend regional agreements, such as the Trans-Pacific Partnership (TPP), are intensifying.

A number of factors work to harmonise the protection of foreign investments by creating overlaps and structural interconnections between agreements. Most-favoured-nations (MFN) provisions in bilateral and regional agreements grant investors rights to more favourable legal protections or entitlements in other investment agreements. An investor covered by an agreement with a MFN clause can therefore invoke the benefits granted to third-party nationals by another agreement of the host state and import them into its relationship with the host State. Furthermore, some agreements, such as the BIT between Hong Kong and Australia (Hong Kong-Australia BIT), require parties to observe any other obligations they may have entered into which may potentially extend to general obligations in international treaties (such as TRIPS). Finally, many states base agreements on model investment treaties that provide a core set of protections such as expropriation and compensation (which encompass measures that diminish or interfere with property rights) and fair and equitable treatment (which can cover the failure to respect an investor’s legitimate expectations, arbitrary, discriminatory or unreasonable treatment, and denial of procedural fairness).

Tobacco Industry’s use of Trade and Investment Law against Regulations affecting Pack Branding
Australia’s Tobacco Plain Packaging Act 2011 and implementing regulations (the 2011 Act) are subject to a complaint in the WTO and a notice of claim from Philip Morris Asia (PM Asia) under the BIT between Hong Kong and Australia. Each of these requests is reflected in subsequent leaked draft texts of the TPP agreement.

The following analysis is divided into four substantive sections. The first three examine how each of PMI’s three proposals is likely to strengthen the tobacco industry’s capacity to prevent the introduction of plain packaging. The fourth briefly examines the extent to which a tobacco-specific exception announced by the USTR, but not yet formally proposed, might nullify the effect of these proposals.

‘HARMONIZATION OF LEGITIMATE, SCIENCE-BASED REGULATIONS’: BETTER REGULATION, POLITICAL ACCESS AND INFORMATION LEVERAGE
Leaked text of a draft TPP chapter on ‘regulatory coherence’ suggests that negotiating parties are seeking to use the TPP to stipulate guidelines for regulatory rulemaking and review along the lines of the Better Regulation and regulatory review agenda in the European Union (EU) and USA. This represents a departure from existing investment agreements and is part of a global process of regulatory reform that draws heavily on US administrative law and its cost-benefit approach to regulatory review. The formal purpose of the chapter is to establish rules for regulatory formation and review that will reduce the likelihood of TPP countries creating and maintaining regulations that are inconsistent with the agreement. Some of the guidelines proposed are consistent with well-informed, methodical decision-making. However, they also promise to increase tobacco companies’ capacity to influence health policy by increasing their access to the policymaking process, augmenting their ability to challenge regulation and reinforcing their existing information advantage.

Three provisions in the draft chapter are likely to facilitate tobacco companies’ policy access. The first is a recommendation that parties to the TPP establish a national coordinating body with the power to review whether regulatory measures adhere to ‘good regulatory practices’. A similar system of review is practiced by the Australian Office of Best Practice Regulation, a regulatory oversight body in Australia which monitors how government departments and agencies develop regulation. In 2010, the office concluded that a draft regulatory impact assessment prepared by the Department of Health and Ageing for the Australian plain packaging law did not satisfy best practice guidelines. The policy was subsequently judged ‘non-compliant’ and earmarked for a postimplementation review within 2 years of it taking effect. Reviews such as this provide tobacco companies with increased opportunities to
Special communication

challenge and shape regulation. In the case of the TPP, which recommends that existing, as well as new, regulation is regularly appraised, these opportunities are likely to be substantial. The second, a recommendation that the national coordinating body ensures that all ministries with an interest in a particular regulation participate in its development, is likely to increase involvement of non-health ministries who are more likely to promote tobacco industry interests. The third provision is a recommendation for collaboration between governments and ‘their respective stakeholders’, including dialogue, meetings and exchange of information. British American Tobacco played a key role in a broad alliance of multinational corporations promoting a similar requirement for stakeholder consultation in EU policymaking and the tobacco industry has subsequently used such requirements in its efforts to undermine Article 5.3 of the WHO Framework Convention on Tobacco Control which, among other things, seeks to reduce tobacco industry access to policymakers. A recommendation in the draft to integrate impact assessments into policy may also enhance tobacco companies’ influence over policymaking. Existing research on British American Tobacco’s efforts to embed impact assessments into the policymaking processes of the EU indicates that their primary aim was to formalise their ability to exploit information asymmetries that commonly characterise business-government relations. Finally, the draft chapter also proposes that governments ensure their regulatory bodies provide access to ‘supporting documentation’ relating to regulatory measures, analyses and data. Such detailed disclosure exacerbates existing information asymmetries between business and government, thereby increasing the industry’s leverage to challenge decision-making.

INVESTOR-STATE DISPUTE SETTLEMENT

Increasing numbers of bilateral and regional agreements have included dispute settlement clauses permitting investors (typically, although not exclusively, corporations) to bring their own claim against governments. Capital exporting states’ continuing preference for ISDS provisions in international agreements is attributed to the belief that overseas corporations are more likely to prevail before an investment tribunal than in domestic courts and their increasing significance is underlined by a fivefold increase in cases under the World Bank’s international arbitration body, the International Centre for the Settlement of Investment Disputes (ICSID), between 1999 and 2012. In practice, ISDS is either overseen by a supervising institution, such as the ICSID or simply follows established rules, such as those of the International Centre for the Settlement of Investment Disputes (ICSID). A leaked draft of the TPP’s investment chapter suggests that claimants will be free to submit claims under the TPP to either the ICSID or under UNCTAD Arbitration Rules or, where claimant and respondent agree, to any other arbitration institution or under any other arbitration rules. One reason PMI is likely to favour ISDS stems from its capacity to discourage parties from introducing plain packaging and produce what is commonly described as ‘regulatory chill’. Although this phenomenon is characteristic of WTO rules and dispute settlement, ISDS is likely to produce a greater chilling effect for several reasons. The first concerns the existence of a pro-business decision-making culture cultivated by arbitral rules and working practices. Arbitral adjudicators are typically international lawyers drawn from commercial practice with no expertise in public health which raises questions about their competence to judge the efficacy of public health regulation and take account of the public policy consequences of their decisions. Arbitral rules also allow lawyers to rotate between roles as arbitrators and advocates for investors in a way that provides limited protection for conflicts of interest. Estimates suggest over 50% of arbitrators act as counsel for investors in other cases while just 10% act for states. Conflicts can arise when arbitrators have ongoing interests in other cases. Moreover, arbitrators are typically appointed and compensated by the parties to the dispute, which may bias decisions in favour of corporate actors who frequently use arbitration. Although repeated appointments of an arbitrator by the same company or law firm are commonly addressed in arbitral rules, repeated appointments by the same side of the investor-state divide are not. These concerns are consistent with the criticism that arbitrators broadly interpret the language contained in investment treaties in a way that prioritises transnational corporations’ economic interests over governments’ right to regulate.

Another reason ISDS is likely to produce a more powerful chilling effect than the WTO’s dispute settlement process concerns the fact that companies can initiate complaints directly, rather than having to lobby a state to act on their behalf. One consequence of this is that the remedies arbitral tribunals can impose on legislating states (compensation or injunctive relief) are linked to the losses incurred by companies from breaches of agreements. In the case of compensation the sums claimed can be vast. Under the Australia-Hong Kong Bilateral Investment Treaty (BIT) (see box 1), Philip Morris Asia (PM Asia) is using ISDS to seek ‘billions of (Australian) dollars’ for potential losses arising from the 2011 Plain Packaging Act and new graphic health warning regulation. The chilling effect is likely to be greater still for low and middle income countries as the calculation of compensation is not tied to their ability to pay. By contrast, under the WTO’s dispute settlement process (box 3), complainant states are effectively limited to imposing retaliatory sanctions commensurate with the value of trade lost resulting from the legislating state’s non-compliance with General Agreement on Tariffs and Trade (GATT)/WTO rules. In pure economic terms, this makes WTO dispute settlement a weaker deterrent to governments considering plain packaging legislation, particularly where the trade in tobacco between legislating and complainant states is not significant, the volume of trade lost to a complainant state is small, or where complainant states’ economies are relatively undeveloped, as this limits their capacity to retaliate in kind.

Tobacco companies’ problems in working through member states under the WTO’s system of dispute settlement is compounded by the fact that many governments may be averse to acting on behalf of tobacco companies. Similarly, low and middle income countries may have concerns about disrupting relations with a more powerful trading partner or a geostrategic ally. By reducing the pool of states that tobacco companies can rely on to initiate a complaint these factors can limit the potential size of the sanctions on legislating states. These limitations of WTO dispute settlement for the tobacco industry are illustrated by the current complaint against Australia in the WTO. Although Ukraine, the lead complainant in this case, is the site of a PMI subsidiary that employs 1400 workers, it has not traded any tobacco with Australia since at least 2005. ISDS is also likely to create a larger deterrent effect because of the greater uncertainty inherent in ISDS decisions. In principle, neither adopted WTO panel and Appellate Body reports, nor decisions of ISDS investment tribunals are formally binding on third parties not involved in the adjudicated dispute. However, in contrast to ISDS tribunals, the WTO operates a de
Special communication

facto system of precedent.87 88 While ISDS tribunals cite previous cases in support of decisions, they do not have to base their decisions on those of previous cases. This produces competing lines of case law which provide a jurisprudential basis for tribunals to arrive at different conclusions in effectively identical cases.11 58 89 90 The absence of an appellate body in investment arbitration and the limited scope to have decisions reviewed is likely to compound this effect.59 80 82

The lack of transparency in investor-state disputes presents an additional source of uncertainty. Proceedings are held in-camera and once a ruling is made by a tribunal there is no general requirement to publish the award or the basis upon which it is made.58 91 The World Bank’s ICSID is now required to make public information on the registration of all requests for conciliation or arbitration, the date and method of termination of proceedings, and, with the consent of the parties, reports of conciliation commissions and awards (where consent is not forthcoming excerpts of the legal reasoning behind tribunal decisions are still published).92 By contrast, no organisation keeps track of United Nations Commission on International Trade Law disputes.93 This lack of transparency creates an information imbalance, which puts low income and middle income countries at a disadvantage as investors with the financial resources to hire major international law firms specialising in this area enjoy greater access to this disparate body of arbitral decisions through professional networks.

These above issues increase the litigation risks for states, which is likely to have a bearing on the decision of low income and middle income countries to withdraw innovative tobacco control measures, or not to innovate at all. The problem is compounded by the high administrative costs involved, which, according to a recent survey by the Organisation of Economic Co-Operation and Development, average over US$8 million per case.58 94 95 96 Moreover, rules for allocating costs among parties are flexible and considered to be an additional source of uncertainty.94

‘A HIGH STANDARD OF PROTECTION FOR TRADEMARKS’: EXTENDED PROTECTION FOR IP TRIPS and ‘TRIPS-plus’

Shortly after TRIPS came into effect, the USA and other developed nations began negotiating for broader and more extensive coverage, increased harmonisation and stronger enforcement mechanisms.55 97 98 Efforts were also made to weaken ‘flexibilities’ and ‘special and differential treatment’ granted to developing countries in a process commonly referred to as ‘TRIPS-Plus’.15 55 97–100

In the present case, PMI’s reply to the US Federal Register indicates that it specifically called for a ‘TRIPS-plus’ chapter to allow it to challenge the introduction of plain packaging.33

The reason behind the request may stem from concerns within PMI that the protection TRIPS gives tobacco companies over pack design is weak or equivocal.101 102 Tobacco companies have consistently argued that plain packaging confrontrves several TRIPS provisions; including Articles 15.4 and 20 and Paris Convention Article 6 quinquies (B).103–108 However, there is a measure of consensus among academic lawyers that the rights granted under TRIPS Article 15.4 and Article 6 quinquies of the Paris Convention are confined to the registration of trademarks, rather than their use and are, therefore, unaffected by plain packaging.102 109–113 There is also a measure of consensus that the strongest argument raised by tobacco companies is that plain packaging violates TRIPS Article 20. Article 20 provides that the use of a trademark in the course of trade should not be unjustifiably encumbered by special requirements.114 Plain packaging is clearly a ‘special requirement’ which is detrimental to the capability of a trademark to distinguish between tobacco products from different companies.102 However, it may be justifiable by virtue of being necessary for public health.11 This interpretation of justifiable is reinforced by Article 8(1), which permits WTO members to adopt measures necessary to protect public health provided they are broadly consistent with other provisions within TRIPS.102 106 Tobacco companies have argued that the proviso merely affirms the right of WTO members to make public policy and does not empower them to breach the provisions of TRIPS.11 103 104 The provision has not yet been the focus of a WTO ruling.115 However, the industry’s interpretation contradicts Paragraph 4 of the Doha Declaration on TRIPS and Public Health (see box 2) and is inconsistent with the WTO Appellate Body’s (see box 3) interpretation of necessary in the context of Article XX(b) of GATT 1994 (see box 4).116 117

Expropriation and minimum standard of treatment

Although a leaked draft chapter on IP proposed by the USA suggests that it is proposing language which might create an affirmative right to use trademarks under certain conditions, in practice this might not prove as important to the prevention of plain packaging than the protections provided to IP in the TPP’s chapter on investment.11 34 36 118 A leaked draft of that chapter defines investment broadly as applying to any assets whose characteristics include ‘a commitment of capital or other resources, expectation of gain or profit, or assumption of risk’,34 which potentially extends the expropriation and minimum standards of treatment provisions in the chapter to the use of trademarks and, therefore, pack design.

Draft Article 12.12 within this chapter requires compensation for ‘indirect expropriation’ of ‘covered investments’ where the effect is to reduce the value of a company’s investments and its future profits.34 Some tribunals have set the threshold at which compensation is payable at a significant and substantial loss, while others have required the near destruction of the value of the investment.11 119 PM Asia’s complaint under the Hong Kong-Australia BIT (box 1) seems to have been made with this latter line of cases in mind, arguing that the 2011 Act ‘virtually eliminates PM’s branded business by expropriating its valuable intellectual property’, transforming the company to a ‘manufacturer of commoditized products with the consequential effect of substantially diminishing the value of PM Asia’s investments in Australia’.69 70 Two (presumably alternative) draft annexes to the chapter aim to limit the use of indirect expropriation. Annex 12-C proposes a ‘case-by-case’ inquiry that considers the economic impact of public policy, the extent to which it interferes with ‘reasonable investment-backed expectations’, and the

Box 2 Paragraph 4 of the Doha Declaration

Paragraph 4 of the Declaration states that TRIPS ‘does not and should not prevent Members from taking measures to protect public health’ and ‘should be interpreted in a manner supportive of World Trade Organisation members’ right to protect public health’. Although the Declaration has been argued to have the same effects as an authoritative interpretation, its substantive scope is restricted to access to medicines for pandemics.11

‘character of government action’. Annex 12-D, by contrast, refers to interference with intangible property rights or interests in an investment that are either ‘severe’ or ‘for an indefinite period’ and ‘disproportionate to the public purpose’.34 These terms are untested and subject to exceptions (‘except in rare circumstances’) which provide arbitrators with some discretion to rule against policies made in good faith to protect public health, and, therefore, create uncertainty in how the protection will be interpreted.34

The broad definition of investment also potentially extends the ‘minimum standard of treatment’ protection under draft Article 12.6.1 to trademarks use.34 The minimum standard includes ‘fair and equitable treatment’34 which has been interpreted by tribunals under existing agreements to include a right to a ‘stable and predictable business environment’ that does not stymie investors’ expectations concerning the profitability or value of their investments.119 Factors considered relevant to the measure include the contribution of the investment to the country, whether the policy is considered arbitrary or unreasonable, and the status of government policy at the time the investment is made.119 Tribunal decisions on the scope of the protection are divergent and, as such, the standard creates a further source of uncertainty.119

THE TOBACCO-SPECIFIC EXCEPTION

Despite the risks these provisions pose in extending tobacco companies’ IP rights, the USTR has announced that the authority of countries to enact measures aimed at reducing tobacco use will be protected under the TPP.120–124 US government agencies are formally prohibited from seeking to reduce or remove other nations’ non-discriminatory restrictions on tobacco marketing.125–128 Consequently, the USTR has produced a draft proposal which would include language in the ‘general exceptions’ chapter partially carving out tobacco in the TPP.129 Although not formally proposed in negotiation at the time of writing, a recently published (May 2012) USTR factsheet on the proposal states it would allow health authorities to adopt regulations that impose ‘science-based restrictions on specific tobacco products/classes in order to safeguard public health’.129,130 The USTR claims that this language will create a ‘safe harbour’ for tobacco regulation, providing ‘greater certainty’ that the provisions in the TPP will not be used to prevent regulation aimed at promoting public health, ‘while retaining important trade disciplines (national treatment, compensation for expropriations and transparency) on tobacco measures’.129

In its present form the degree of protection this proposal would give to public health policy is unclear. The proposal covers regulations adopted by a health authority and, therefore, potentially does not extend to legislation or regulations by non-health authorities on matters relating, for example, to tax and IP.131 In addition to this, the proposal does not seem to extend to claims alleging that regulation has had the effect of expropriating a company’s assets without providing compensation.131 The ‘science-based’ test also creates uncertainty. It represents a qualitatively different test to Article 8(1) of TRIPS and may impose a more rigid process of evaluation than that outlined by the Appellate Body in relation to Article XX(b) of GATT 1994 (box 4). The health exception in GATT applies to measures that

Box 3 World Trade Organisation (WTO) dispute settlement process

The Dispute Settlement Body (DSB) consists of all WTO members and has the responsibility for settling disputes under General Agreement on Tariffs and Trade (GATT)/WTO rules. It establishes panels of experts to consider cases in response to requests from complainant states. The panel produces a report which, in practice, becomes the DSB’s ruling at which point it can be appealed by either side. Appeals are adjudicated by three members of a rotating seven-member Appellate Body broadly representative of the WTO’s membership. The appeal can uphold, modify or reverse the panel’s legal findings and conclusions. Rejection of an appeal report by the DSB is only possible by consensus.

If the respondent state fails to comply with a ruling within a reasonable period, it is required to enter into negotiations with the complainant state to determine mutually acceptable compensation. In the absence of an agreement the complainant can apply to the DSB for permission to impose trade sanctions against the respondent. In principle, the sanctions should be imposed in the same sector as the dispute. If this is not practical or effective, the sanctions can be imposed in a different sector under the same agreement or, in exceptional cases, under another WTO agreement.

Box 4 Appellate body’s report into Brazil’s measures affecting imports of retreaded tyres

General Agreement on Tariffs and Trade (GATT) Article XX(b) exempts a Member’s measure from compliance with the provisions of GATT where that measure is ‘necessary to protect human, animal or plant life or health.’117 In 2007 the World Trade Organisation (WTO)’s Appellate Body outlined the following principles which, if subsequently applied to Article 8, are unlikely to favour Ukraine’s current complaint in the WTO:102 116 117

- Certain complex public health or environmental problems may be tackled only with a comprehensive policy comprising a multiplicity of interacting measures;
- In the short term it may prove difficult to isolate the contribution to public health of one specific measure from those attributable to the other measures that are part of the same comprehensive policy;
- Results obtained from certain preventive actions to reduce the incidence of diseases may manifest themselves only after a certain period of time and may only be capable of evaluation after a period of time;
- An import ban under Article XX(b) can only be justified where it brings about a material contribution to the achievement of its objective;
- A material contribution can be established with reference to evidence or data but also on the basis of quantitative projections in the future, or qualitative reasoning based on a set of hypotheses that are tested and supported by sufficient evidence;
- The selection of a methodology to assess a measure’s contribution is a function of the nature of the risk, the objective pursued, and the level of protection sought, and depends on the nature, quantity and quality of evidence existing at the time the analysis is made.117

Special communication

are ‘necessary.’ The WTO’s Appellate Body has ruled that a necessary measure must contribute to the health objective, but the contribution need not be proven with ‘science-based’ evidence (see box 4). In this regard, the proposed exception may be narrower than the existing health exception. Moreover, by creating uncertainty and providing another avenue for tobacco companies to litigate it is likely to discourage parties from introducing plain packaging.13,11

CONCLUSION

Trade and investment agreements have been criticised for transferring state decision-making from the national to the international level and providing transnational corporations with a supranational court of appeal with which to challenge the capacity of governments to introduce new public health legislation.25 PM Asia’s continuing action against the Australian government under the Hong Kong-Australia BIT given its defeat in the Australian High Court over the 2011 Act illustrates this point well.26 121 PMI’s formal request to the USTR that the TPP be used to extend IP rights, harmonise the process of regulatory formation, and provide a comprehensive system of ISDS reflect the contents of leaked drafts of the TPP agreement. These suggest the TPP will extend IP protection to trademark use, strengthen corporate influence in regulatory formation, and provide tobacco companies with extensive powers to litigate against governments directly. Although the extension of IP protection is subject to exceptions for measures aimed at promoting public health, the precise scope of these exceptions is unclear. Consequently, all three measures are likely to increase the tobacco industry’s policy influence and to deter governments from introducing plain packaging, albeit in different ways. First, by increasing litigation risk for legislating states, the extension of IP protection to trademark use will increase tobacco companies’ power to present the costs associated with plain packaging and other policies affecting pack design as prohibitively expensive. Likewise, proposals such as regulatory review, stakeholder consultation and the use of impact assessments provide the industry with a range of tools to access and feed information into health policymaking. Combined with the TPP’s proposal for states to provide access to ‘supporting documentation’ relating to regulatory measures, analyses and data, which may exacerbate existing information asymmetries between states and multinational corporations, these reforms are likely to facilitate challenges to regulatory innovation under international law.24 By underpinning these measures with ISDS, which increases the economic costs associated with litigation and institutionally embeds uncertainty in treaty interpretation, the TPP provides a powerful new toolbox for the industry in preventing the introduction of plain packaging and other innovative health measures.

Finally, the lack of transparency in the TPP negotiations illustrates the limitations inherent in the state-centric nature of Article 5.3 of the WHO Framework Convention on Tobacco Control. Article 5.3 aims to limit tobacco industry involvement in health policy by, among other things, requiring parties to the Convention to make interactions between the tobacco industry and public officials as transparent as possible. The USA is a non-party to the Convention and is, therefore, under no obligation to make public any involvement of tobacco companies, either directly or through third parties, in TPP policymaking. This enables the tobacco industry to undermine APEC states’ efforts to implement Article 5.3 and influence health policy remotely through TPP negotiations.

Key messages

- The TPP threatens to increase the tobacco industry’s policy influence and increase the litigation risks of plain packaging legislation and other innovative tobacco control measures.
- Parties to the Framework Convention on Tobacco Control should consider how Article 5.3 can be implemented to prevent tobacco companies from influencing public health policy remotely through trade and investment agreements.
- Agreements involving non-party states raise additional complications which need to be raised during treaty negotiations.

Acknowledgements

We thank Cathy Flower for providing administrative support for the project and Jeff Collin for advice on relevant sources. The study was supported by Grant Number R01CA160695 from the National Cancer Institute at the US National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Gary Fooks and Anna Gilmore are members of the UK Centre for Tobacco Control Studies (UKCCTS), a UK Centre for Public Health Excellence. Funding to UKCCTS from the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council, the Medical Research Council and the National Institute of Health Research, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged.

Contributors

The study was conceived and designed by GF. GF analysed the data and wrote the first draft of the manuscript. ABG contributed to the writing of the manuscript. ICMJE criteria for authorship are met. GF and ABG agree with manuscript results and conclusions.

Competing interests

None.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES

Special communication


103 International Centre for Settlement of Investment Disputes. CISCD convention, regulations and rules. general functions of the Secretariat 2006; Regulation 22.


International trade law, plain packaging and tobacco industry political activity: the Trans-Pacific Partnership
Gary Fooks and Anna B Gilmore

Tob Control published online June 20, 2013

Updated information and services can be found at:
http://tobaccocontrol.bmj.com/content/early/2013/06/19/tobaccocontrol-2012-050869

These include:

References
This article cites 44 articles, 11 of which you can access for free at:
http://tobaccocontrol.bmj.com/content/early/2013/06/19/tobaccocontrol-2012-050869#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (258)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/